Protocol Ledger

NCT06737250 · Phase II · RECRUITING

NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL

Interventional Phase II clinical trial protocol NCT06737250 sponsored by NOBO Medicine in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-11-25 Enrollment: 33 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06737250
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)33 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06737250
Protocol FieldVerified Registry Value
NCT IdentifierNCT06737250
Consolidated Lead SponsorNOBO Medicine
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment33 participants (ESTIMATED)
Registered Start Date2024-11-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06737250
Hospital Research SiteLocationSite Profile
Chonnam National University Hwasun HospitalHwasun, South KoreaOpen Hospital Dossier ->
Seoul National University Bundang HospitalSeongnam, South KoreaOpen Hospital Dossier ->
Asan Medical CenterSeoul, South KoreaOpen Hospital Dossier ->
Korea University Anam HospitalSeoul, South KoreaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI